journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://read.qxmd.com/read/30755085/higher-ebv-response-is-associated-with-more-severe-gray-matter-and-lesion-pathology-in-relapsing-multiple-sclerosis-patients-a-case-controlled-magnetization-transfer-ratio-study
#1
Dejan Jakimovski, Murali Ramanathan, Bianca Weinstock-Guttman, Niels Bergsland, Deepa P Ramasamay, Ellen Carl, Michael G Dwyer, Robert Zivadinov
BACKGROUND: Epstein-Barr virus (EBV) infection has been associated with higher clinical activity and risk of multiple sclerosis (MS). OBJECTIVE: To evaluate associations between EBV-specific humoral response and magnetization transfer ratio (MTR)-derived measure in MS patients and healthy controls (HCs). METHODS: The study included 101 MS patients (69 relapsing-remitting multiple sclerosis (RRMS) and 32 secondary-progressive multiple sclerosis (SPMS)) and 41 HCs who underwent clinical, serological, and magnetic resonance imaging (MRI) investigations...
February 13, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30747579/ms-progression-is-predominantly-driven-by-age-related-mechanisms-yes
#2
Antonio Scalfari
No abstract text is available yet for this article.
February 12, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30747576/ms-progression-is-predominantly-driven-by-age-related-mechanisms-commentary
#3
Burcu Zeydan, Orhun H Kantarci
No abstract text is available yet for this article.
February 12, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30747571/ms-progression-is-predominantly-driven-by-age-related-mechanisms-no
#4
Marisa McGinley, Daniel Ontaneda
No abstract text is available yet for this article.
February 12, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30741108/effect-of-disease-modifying-therapies-on-subcortical-gray-matter-atrophy-in-multiple-sclerosis
#5
Elias S Sotirchos, Natalia Gonzalez-Caldito, Blake E Dewey, Kathryn C Fitzgerald, Jeffrey Glaister, Angeliki Filippatou, Esther Ogbuokiri, Sydney Feldman, Ohemaa Kwakyi, Hunter Risher, Ciprian Crainiceanu, Dzung L Pham, Peter C Van Zijl, Ellen M Mowry, Daniel S Reich, Jerry L Prince, Peter A Calabresi, Shiv Saidha
BACKGROUND: The effects of disease-modifying therapies (DMTs) on region-specific brain atrophy in multiple sclerosis (MS) are unclear. OBJECTIVE: To determine the effects of higher versus lower efficacy DMTs on rates of brain substructure atrophy in MS. METHODS: A non-randomized, observational cohort of people with MS followed with annual brain magnetic resonance imaging (MRI) was evaluated retrospectively. Whole brain, subcortical gray matter (GM), cortical GM, and cerebral white matter (WM) volume fractions were obtained...
February 11, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30741103/the-efficacy-of-the-modified-story-memory-technique-in-progressive-ms
#6
Nancy D Chiaravalloti, Nancy B Moore, John DeLuca
BACKGROUND: Impairments in new learning and memory are common in individuals with multiple sclerosis (MS), negatively impacting everyday life, including occupational and social functioning. OBJECTIVE: This study examined the efficacy of the modified Story Memory Technique (mSMT) in a progressive multiple sclerosis (PMS) sample through a double-blind, placebo-controlled, randomized clinical trial (RCT). METHODS: Thirty (30) individuals with PMS, naïve to the mSMT, were randomized to the treatment or placebo control group...
February 11, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30741090/lack-of-association-between-toxocara-canis-and-multiple-sclerosis-a-population-based-case-control-study
#7
Calogero Edoardo Cicero, Francesco Patti, Salvatore Lo Fermo, Loretta Giuliano, Cristina Rascunà, Clara Grazia Chisari, Emanuele D'Amico, Vincenza Paradisi, Benoît Marin, Pierre-Marie Preux, Antonia Mantella, Alessandro Bartoloni, Mario Zappia, Alessandra Nicoletti
No abstract text is available yet for this article.
February 11, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30730246/the-spectrum-of-spinal-cord-lesions-in-a-primate-model-of-multiple-sclerosis
#8
Jennifer A Lefeuvre, Joseph R Guy, Nicholas J Luciano, Seung-Kwon Ha, Emily Leibovitch, Mathieu D Santin, Afonso C Silva, Steven Jacobson, Stéphane Lehéricy, Daniel S Reich, Pascal Sati
BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) in the common marmoset is a nonhuman primate model of multiple sclerosis (MS) that shares numerous clinical, radiological, and pathological features with MS. Among the clinical features are motor and sensory deficits that are highly suggestive of spinal cord (SC) damage. OBJECTIVE: To characterize the extent and nature of SC damage in symptomatic marmosets with EAE using a combined magnetic resonance imaging (MRI) and histopathology approach...
February 7, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30730244/oral-d-aspartate-enhances-synaptic-plasticity-reserve-in-progressive-multiple-sclerosis
#9
Carolina G Nicoletti, Fabrizia Monteleone, Girolama A Marfia, Alessandro Usiello, Fabio Buttari, Diego Centonze, Francesco Mori
BACKGROUND: Synaptic plasticity reserve correlates with clinical recovery after a relapse in relapsing-remitting forms of multiple sclerosis (MS) and is significantly compromised in patients with progressive forms of MS. These findings suggest that progression of disability in MS is linked to reduced synaptic plasticity reserve. D-Aspartate, an endogenous aminoacid approved for the use in humans as a dietary supplement, enhances synaptic plasticity in mice. OBJECTIVE: To test whether D-Aspartate oral intake increases synaptic plasticity reserve in progressive MS patients...
February 7, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30730238/apathy-as-a-herald-of-cognitive-changes-in-multiple-sclerosis-a-2-year-follow-up-study
#10
Simona Raimo, Daniele Spitaleri, Luigi Trojano, Gabriella Santangelo
BACKGROUND: Behavioral symptoms, such as apathy and depression, are common in multiple sclerosis (MS) but their relationship with cognitive and clinical characteristics often remains underinvestigated and not monitored over time. OBJECTIVE: The aim of this study was to assess the evolution of cognitive profile of patients affected by MS in relation to apathy and depression using a 2-year follow-up study. METHODS: Two years after the first assessment, 100 of 125 MS patients were re-evaluated on a comprehensive neuropsychological battery, and on specific scales for assessment of apathy (Apathy Evaluation Scale-Self-reported) and depression (Hamilton Depression Rating Scale)...
February 7, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30730236/early-predictors-of-epilepsy-and-subsequent-relapse-in-children-with-acute-disseminated-encephalomyelitis
#11
Thomas Rossor, Christina Benetou, Sukhvir Wright, Sophie Duignan, Karine Lascelles, Robert Robinson, Krishna Das, Olga Ciccarelli, Evangeline Wassmer, Cheryl Hemingway, Ming Lim, Yael Hacohen
OBJECTIVE: To identify predictors of epilepsy and clinical relapses in children presenting with acute disseminated encephalomyelitis (ADEM). METHODS: Children presenting with ADEM between 2005 and 2017 and tested clinically for MOG-Ab were identified from three tertiary paediatric neurology centres in the United Kingdom. Patients were followed up for a median of 6 years (range, 1-16 years). RESULTS: A total of 74 children were studied (38 females; median age at first presentation: 4...
February 7, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30730233/white-matter-nulled-mprage-at-7t-reveals-thalamic-lesions-and-atrophy-of-specific-thalamic-nuclei-in-multiple-sclerosis
#12
Vincent Planche, Jason H Su, Sandy Mournet, Manojkumar Saranathan, Vincent Dousset, May Han, Brian K Rutt, Thomas Tourdias
BACKGROUND: Investigating the degeneration of specific thalamic nuclei in multiple sclerosis (MS) remains challenging. METHODS: White-matter-nulled (WMn) MPRAGE, MP-FLAIR, and standard T1-weighted magnetic resonance imaging (MRI) were performed on MS patients ( n = 15) and matched controls ( n = 12). Thalamic lesions were counted in individual sequences and lesion contrast-to-noise ratio (CNR) was measured. Volumes of 12 thalamic nuclei were measured using an automatic segmentation pipeline specifically developed for WMn-MPRAGE...
February 7, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30663514/area-postrema-syndrome-another-feature-of-anti-gfap-encephalomyelitis
#13
Jonathan Ciron, Fanny Sourdrille, Damien Biotti, Thierry Tchoumi, Anne Ruiz, Raphaël Bernard-Valnet, Nicolas Maubeuge, Romain Marignier
Anti-Glial fibrillary acidic protein (GFAP) encephalomyelitis is a recently described entity and while the spectrum of this disease has been explored, further research is needed to fully describe its phenotype. Area postrema syndrome (APS) is usually associated with neuromyelitis optica spectrum disorders (NMOSDs), whereas no case of APS has been previously reported with anti-GFAP encephalomyelitis. In this article, we report a case of APS in a 41-year-old woman in the context of anti-GFAP encephalomyelitis...
January 21, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30663500/area-postrema-syndrome-in-autoimmune-gfap-astrocytopathy
#14
Elia Sechi, Eoin P Flanagan
No abstract text is available yet for this article.
January 21, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30657420/severe-meningo-encephalitis-after-daclizumab-therapy-for-multiple-sclerosis
#15
Lidia Stork, Wolfgang Brück, Phillip von Gottberg, Ulrich Pulkowski, Florian Kirsten, Markus Glatzel, Sebastian Rauer, Franziska Scheibe, Helena Radbruch, Eckhard Hammer, Klarissa H Stürner, Barbara Kaulen, Christoph Heesen, Frank Hoffmann, Sebastian Brock, Marc Pawlitzki, Tobias Bopp, Imke Metz
BACKGROUND: Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018. OBJECTIVE AND METHODS: This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy. RESULTS: Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7)...
January 18, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30657011/imaging-correlates-of-hand-motor-performance-in-multiple-sclerosis-a-multiparametric-structural-and-functional-mri-study
#16
Claudio Cordani, Alessandro Meani, Federica Esposito, Paola Valsasina, Bruno Colombo, Elisabetta Pagani, Paolo Preziosa, Giancarlo Comi, Massimo Filippi, Maria A Rocca
BACKGROUND: Hand motor impairment has considerable effects on daily-life activities of patients with multiple sclerosis (pwMS). Understanding its anatomo-functional substrates is relevant to provide more specific therapeutic interventions. OBJECTIVES: To investigate the association between hand motor performance and anatomo-functional magnetic resonance imaging (MRI) abnormalities in pwMS. METHODS: A total of 134 healthy controls (HC) and 366 pwMS underwent the Nine-Hole-Peg-Test (9HPT), structural and resting state (RS) functional MRI...
January 18, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30657008/the-spectrum-of-acute-cardiopulmonary-events-associated-with-multiple-sclerosis-exacerbations
#17
Cristina Valencia-Sanchez, Brent P Goodman, Jonathan L Carter, Dean M Wingerchuk
Diverse acute neurological injuries may cause acute cardiopulmonary events including neurogenic pulmonary edema (NPE) and neurogenic stunned myocardium (NSM). The mechanism is probably mediated by sympathetic nervous system activation. Focal central nervous system (CNS) lesions, such as demyelinating lesions in multiple sclerosis (MS), may also cause cardiopulmonary disturbances. We aim to review the acute cardiopulmonary events associated with MS relapses. We performed a literature search using PubMed, and selected case reports of acute cardiac and/or pulmonary events related to MS exacerbations...
January 18, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30657002/minimal-clinically-important-difference-of-improvement-on-the-arm-function-in-multiple-sclerosis-questionnaire-amsq
#18
Caspar Ep van Munster, Levent Kaya, Morgan Obura, Nynke F Kalkers, Bernard Mj Uitdehaag
BACKGROUND: The Arm Function in Multiple Sclerosis Questionnaire (AMSQ) has been developed to assess upper extremity function of patients with multiple sclerosis (MS). A minimal clinically important difference (MCID) value has not been determined yet. OBJECTIVE: The objective of this study is to determine an MCID for AMSQ. METHODS: We used the sensitivity- and specificity-based approach with dichotomized global perceived effect as an anchor...
January 18, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30638421/the-role-of-infections-in-multiple-sclerosis
#19
Mariano Marrodan, Lucas Alessandro, Mauricio F Farez, Jorge Correale
Several lines of evidence suggest that multiple sclerosis (MS), like other autoimmune diseases, may be triggered by microbial infections. Pathogens associated with development or exacerbation of MS include bacteria, such as Chlamydia pneumoniae, Staphylococcus aureus-produced enterotoxins that function as superantigens, and viruses of the Herpesviridae (Epstein-Barr virus and human herpes virus 6) and human endogenous retrovirus families. However, to date, no single pathogen has been accepted as causal agent...
January 14, 2019: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/30632449/instead-of-tweaking-the-diagnostic-criteria-for-ms-in-those-with-cis-we-should-develop-diagnostic-criteria-that-distinguish-ms-from-other-conditions-commentary
#20
Franz Fazekas
No abstract text is available yet for this article.
January 11, 2019: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"